Hereditary Cancer Testing Market by Diagnosis Type (Biopsy, Imaging and Others), By End-User (Hospitals, Clinics, and Diagnostic Centers), and by Region-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 - 2029

                                          
Abstract
                    
The report covers forecast and analysis for the hereditary cancer testing market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the hereditary cancer testing market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hereditary cancer testing market on a global level.

In order to give the users of this report a comprehensive view of the hereditary cancer testing market, we have included competitive landscape and analysis of Porter’s Five Forces model of the market. The study encompasses a market attractiveness analysis, where diagnosis type, end-user, and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments in the market, including acquisitions & mergers, new product type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market in global and regional basis.

The study provides a decisive view of the hereditary cancer testing market by segmenting the market based on diagnosis type, end-user, and regions. All the segments have been analyzed based on present and the future trends and the market is estimated from 2018 to 2024.

Based on diagnosis type, the hereditary cancer testing market is segmented as biopsy, imaging, and others. Based on end-user, the hereditary cancer testing market is segmented as hospitals, clinics, and diagnostic centers.

Growing demand for non-invasive techniques for detection of hereditary cancer coupled with government funding for improvement of rapid diagnostics and rising concerns of hereditary cancer are the major driving factors of hereditary cancer testing market. Difficulties in accessing the complete genomic data for early detection and prevention will influence the market growth during the forecast period.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries including the U.S., Germany, France, U.K., China, Japan, India, and Brazil. This segment includes demand for hereditary cancer testing market based on individual segment and applications in all the regions and countries.

The report also includes detailed profiles of end players such as Myriad Genetics, Myogenes, Laboratory Corporation of America, Biocartis NV, Quest Diagnostics, Pathway Genomics, Invitae Corporation, and Strand Life Sciences Pvt. Ltd., among others.

This report segments the global hereditary cancer testing market as follows:

Global Hereditary Cancer Testing Market: by Diagnosis Type

	Biopsy
	Imaging
	Others

Global Hereditary Cancer Testing Market: by End-User Channel

	Hospitals
	Clinics
	Diagnostic Centers

Global Hereditary Cancer Testing Market: by Region

	North America
	
		The U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	The Middle East and Africa